Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir

被引：0
|
作者：
Kagan, R
Ross, L
Winters, M
Merigan, T
Heseltine, P
Lewinski, M
机构：
[1] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA
[2] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[3] Stanford Univ, Ctr AID Res, Stanford, CA 94305 USA
来源：
ANTIVIRAL THERAPY | 2005年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [21] Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors
    Sluis-Cremer, Nicolas
    Sheen, Chih-Wei
    Zelina, Shannon
    Torres, Pedro S. Argoti
    Parikh, Urvi A.
    Mellors, John W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) : 48 - 53
  • [22] The HIV-1 protease mutation K55R is associated with the presence of the M461/L mutation
    Morgan, E
    Pillay, D
    Cane, P
    Kleim, JP
    Tisdale, M
    Maguire, M
    Macmanus, S
    Yates, P
    Elston, R
    ANTIVIRAL THERAPY, 2003, 8 (03) : U57 - U58
  • [23] Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase
    McCallum, Matthew
    Oliveira, Maureen
    Ibanescu, Ruxandra-Ilinca
    Kramer, Victor G.
    Moisi, Daniela
    Asahchop, Eugene L.
    Brenner, Bluma G.
    Harrigan, P. Richard
    Xu, Hongtao
    Wainberg, Mark A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4681 - 4688
  • [24] Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance
    Das, Kalyan
    Bandwar, Rajiv P.
    White, Kirsten L.
    Feng, Joy Y.
    Sarafianos, Stefan G.
    Tuske, Steven
    Tu, Xiongying
    Clark, Arthur D., Jr.
    Boyer, Paul L.
    Hou, Xiaorong
    Gaffney, Barbara L.
    Jones, Roger A.
    Miller, Michael D.
    Hughes, Stephen H.
    Arnold, Eddy
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (50) : 35092 - 35100
  • [25] Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir
    Steve Tuske
    Stefan G Sarafianos
    Arthur D Clark
    Jianping Ding
    Lisa K Naeger
    Kirsten L White
    Michael D Miller
    Craig S Gibbs
    Paul L Boyer
    Patrick Clark
    Gang Wang
    Barbara L Gaffney
    Roger A Jones
    Donald M Jerina
    Stephen H Hughes
    Eddy Arnold
    Nature Structural & Molecular Biology, 2004, 11 : 469 - 474
  • [26] Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir
    Kulkarni, Rima
    Feng, Joy Y.
    Miller, Michael D.
    White, Kirsten L.
    ANTIVIRAL RESEARCH, 2014, 101 : 131 - 135
  • [27] High-resolution structures of HIV-1 RT/RNA:DNA ternary complexes with tenofovir diphosphate and dATP
    Das, K.
    Bandwar, R.
    Bauman, J.
    Tuske, S.
    Hughes, S. H.
    Arnold, E.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A19 - A19
  • [28] Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes
    Asahchop, Eugene L.
    Oliveira, Maureen
    Wainberg, Mark A.
    Brenner, Bluma G.
    Moisi, Daniela
    Toni, Thomas d'Aquin
    Tremblay, Cecile L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (02) : 600 - 607
  • [29] Efavirenz/emtricitabine/tenofovir disoproxil fumarateDevelopment of drug resistant mutation in HIV-1 infection: case report
    Reactions Weekly, 2017, 1633 (1) : 300 - 300
  • [30] The Lys103Asn mutation of HIV-1 RT:: A novel mechanism of drug resistance
    Hsiou, Y
    Ding, JP
    Das, K
    Clark, AD
    Boyer, PL
    Lewi, P
    Janssen, PAJ
    Kleim, JP
    Rösner, M
    Hughes, SH
    Arnold, E
    JOURNAL OF MOLECULAR BIOLOGY, 2001, 309 (02) : 437 - 445
12345